162 related articles for article (PubMed ID: 28107281)
21. Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent?
Gaspar R; Liberal R; Macedo G
J Crohns Colitis; 2017 Oct; 11(11):1403-1404. PubMed ID: 28531313
[No Abstract] [Full Text] [Related]
22. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis.
Cucinotta U; Dipasquale V; Costa S; Pellegrino S; Ramistella V; Romano C
J Clin Pharm Ther; 2022 Feb; 47(2):254-256. PubMed ID: 34278581
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Jin Y; Lin Y; Lin LJ; Zheng CQ
World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab for the treatment of ulcerative colitis.
Stallmach A; Schmidt C; Teich N
Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
[TBL] [Abstract][Full Text] [Related]
26. New-Onset Diffuse Parenchymal Lung Disease in a 52-Year-Old Woman With Ulcerative Colitis.
De Backer E; Bode H; Baert F
Gastroenterology; 2020 Feb; 158(3):478-479. PubMed ID: 31560891
[No Abstract] [Full Text] [Related]
27. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
28. Positioning Infliximab and Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis.
Sheehan JL; Cohen-Mekelburg S
Gastroenterology; 2022 May; 162(6):1764-1765. PubMed ID: 34864070
[No Abstract] [Full Text] [Related]
29. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
30. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
Conrad MA; Stein RE; Maxwell EC; Albenberg L; Baldassano RN; Dawany N; Grossman AB; Mamula P; Piccoli DA; Kelsen JR
Inflamm Bowel Dis; 2016 Oct; 22(10):2425-31. PubMed ID: 27598742
[TBL] [Abstract][Full Text] [Related]
32. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
[TBL] [Abstract][Full Text] [Related]
33. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
34. Letter: Vedolizumab in Pregnancy.
Sheridan J; Cullen G; Doherty G
J Crohns Colitis; 2017 Aug; 11(8):1025-1026. PubMed ID: 27993997
[No Abstract] [Full Text] [Related]
35. Herpes Zoster in a Patient With Ulcerative Colitis After Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?
Wu N; Li H; Zhang J; Huang W
Inflamm Bowel Dis; 2022 Feb; 28(2):e22-e23. PubMed ID: 34480561
[No Abstract] [Full Text] [Related]
36. Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis.
Meszaros M; Pageaux GP; Altwegg R
J Crohns Colitis; 2016 Feb; 10(2):236. PubMed ID: 26449788
[No Abstract] [Full Text] [Related]
37. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
38. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
40. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
